Endothelin Receptor Antagonism by Tezosentan Attenuates Lung Injury Induced by Aortic Ischemia-Reperfusion

Basit Öğe Kaydı
dc.contributor.authorKiris, Ilker
dc.contributor.authorNarin, Cueneyt
dc.contributor.authorGulmen, Senol
dc.contributor.authorYilmaz, Nigar
dc.contributor.authorSutcu, Recep
dc.contributor.authorKapucuoglu, Nilguen
dc.date.accessioned2020-03-26T17:38:33Z
dc.date.available2020-03-26T17:38:33Z
dc.date.issued2009
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractTezosentan is a novel dual endothelin receptor antagonist. The purpose of this study was to examine the effect of tezosentan on lung injury induced by abdominal aortic ischemia-reperfusion (IR) in rats. Thirty-two Wistar-albino rats were randomized into four groups (eight per group) as follows: control group (sham laparotomy), aortic IR group (120 min ischemia and 120 min reperfusion), aortic IR + tezosentan group (a bolus intravenous injection of 10 mg/kg tezosentan before ischemia plus continuous intravenous infusion of 1 mg/kg/hr tezosentan during 120 min ischemia and 120 min reperfusion), and control + tezosentan. Blood and lung tissue samples were obtained for biochemical analysis. Protein concentrations in bronchoalveolar lavage fluid and lung wet/dry weight ratios were measured. A histological evaluation was also done. Aortic IR significantly increased (p < 0.05 vs. control group) and tezosentan significantly decreased (p < 0.05 vs. aortic IR group) the plasma level of tumor necrosis factor-alpha; lung tissue levels of malondialdehyde, catalase, and myleperoxidase; and protein concentration in bronchoalveolar lavage fluid and lung wet/dry weight ratio. Histological evaluation showed that tezosentan attenuated the morphological changes associated with lung injury. The results of this study indicate that tezosentan attenuates lung injury induced by aortic IR in rats. We propose that this protective effect of tezosentan is due to (1) reduced systemic inflammatory response, (2) reduced oxidative stress and lipid peroxidation in lung tissue, (3) reduced pulmonary microvascular leakage, and (4) inhibition of leukocyte infiltration into lung tissue.en_US
dc.description.sponsorshipActelion (Istanbul, Turkey)en_US
dc.description.sponsorshipThe authors are grateful for the kind gift of tezosentan flacon from Actelion Pharmaceuticals (Allschwill, Switzerland). The commercial kits for the biochemical analyses were sponsored by Actelion (Istanbul, Turkey).en_US
dc.identifier.doi10.1016/j.avsg.2008.10.003en_US
dc.identifier.endpage391en_US
dc.identifier.issn0890-5096en_US
dc.identifier.issn1615-5947en_US
dc.identifier.issue3en_US
dc.identifier.pmid19135850en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage382en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.avsg.2008.10.003
dc.identifier.urihttps://hdl.handle.net/20.500.12395/23513
dc.identifier.volume23en_US
dc.identifier.wosWOS:000266402700016en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherELSEVIER SCIENCE INCen_US
dc.relation.ispartofANNALS OF VASCULAR SURGERYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.titleEndothelin Receptor Antagonism by Tezosentan Attenuates Lung Injury Induced by Aortic Ischemia-Reperfusionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu